US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Achieve Life Sciences, Inc. - Common Shares (NQ:ACHV)

7.240 -0.290 (-3.85%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Achieve Life Sciences, Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
LCID Stock Alert: Lucid Announces CFO Departure ↗
Lucid stock is falling on Tuesday as investors in LCID react to the company's CFO departing immediately to pursue other opportunities. 
Via InvestorPlace
News headline image
Why Is Achieve Life Sciences (ACHV) Stock Down 25% Today? ↗
Achieve Life Sciences stock is falling on Tuesday after the company provided ACHV investors with an FDA update concerning an NDA. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
PVH To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket ↗
Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion. 
Via Benzinga
News headline image
Recap: Achieve Life Sciences Q1 Earnings ↗
 
Via Benzinga
News headline image
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
Topline Data Expected in 2Q 2023 
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading! 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Why CohBar Shares Are Trading Lower By 161%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Achieve Life Sciences's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Topline Data Expected in 2Q 2023 
From Achieve Life Sciences
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Can't Kick the Bud? Achieve's Cytisinicline Proves Promising in Phase 3 Smoking Cessation Trial ↗
Achieve Life Sciences Inc (NASDAQ: ACHV) announced topline results from the second  
Via Benzinga
News headline image
BJ's Wholesale, Kingsoft Cloud, Zoom Video And Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded mixed, with the Nasdaq Composite dropping around 30 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Achieve Life Sciences Inc. (NASDAQ: ACHV) Climbs to New 52-Week High
Via Investor Brand Network
News headline image
Want To Quit Smoking? Achieve Life Sciences Reports Successful E-Cigarette Cessation Benefit With Cytisinicline Treatment ↗
 
Via Benzinga
News headline image
Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Topline Data Expected in 2Q 2023 
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Top 5 Health Care Stocks That May Collapse ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Achieve Life Sciences Announces Refresh to Board of Directors
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences Announces Granting of New Hire Inducement Award
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences Announces Granting of New Hire Inducement Award
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference
From Achieve Life Sciences
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation
From Achieve Life Sciences
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why ObsEva Shares Are Trading Higher By Over 70%; Here Are 21 Stocks Moving Premarket ↗
Gainers ObsEva SA (NASDAQ: OBSV) shares rose 71.9% to $0.2848 in pre-market trading after the company reported the sale of Ebopiprant license agreement to XOMA for up to $113 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >